A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma
Huan Zhang, Man Liu, Xia Xiao, Hairong Lv, Yanyu Jiang, Xin Li, Ting Yuan, Mingfeng Zhao
Abstract
The patients were enrolled in clinical trials registered as ChiCTR1800017051.
Topics & Concepts
MedicineInternal medicineMultiple myelomaCytokine release syndromeRefractory (planetary science)Chimeric antigen receptorCD38OncologyGastroenterologyImmunologyImmunotherapyStem cellCD34CancerAstrobiologyPhysicsBiologyGeneticsCAR-T cell therapy researchMultiple Myeloma Research and TreatmentsNanowire Synthesis and Applications